3.67
price down icon3.93%   -0.15
 
loading
전일 마감가:
$3.82
열려 있는:
$3.81
하루 거래량:
35,527
Relative Volume:
0.32
시가총액:
$227.64M
수익:
-
순이익/손실:
$-66.86M
주가수익비율:
-3.0583
EPS:
-1.2
순현금흐름:
$-58.82M
1주 성능:
-1.87%
1개월 성능:
-5.41%
6개월 성능:
-41.28%
1년 성능:
+9.55%
1일 변동 폭
Value
$3.54
$3.81
1주일 범위
Value
$3.54
$4.205
52주 변동 폭
Value
$2.60
$7.77

디자인 테라 Stock (DSGN) Company Profile

Name
명칭
Design Therapeutics Inc
Name
전화
858-293-4900
Name
주소
6005 HIDDEN VALLEY ROAD, CARLSBAD
Name
직원
56
Name
트위터
Name
다음 수익 날짜
2025-03-10
Name
최신 SEC 제출 서류
Name
DSGN's Discussions on Twitter

DSGN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
DSGN
Design Therapeutics Inc
3.67 227.64M 0 -66.86M -58.82M -1.20
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.89 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
519.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
319.26 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
559.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
240.94 28.51B 3.81B -644.79M -669.77M -6.24

디자인 테라 Stock (DSGN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-07 업그레이드 Piper Sandler Neutral → Overweight
2023-11-14 다운그레이드 Piper Sandler Overweight → Neutral
2023-08-15 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2023-08-15 다운그레이드 SVB Securities Outperform → Market Perform
2023-08-15 다운그레이드 Wedbush Outperform → Neutral
2023-05-04 업그레이드 Goldman Sell → Neutral
2022-06-10 개시 Wedbush Outperform
2022-05-02 개시 RBC Capital Mkts Outperform
2022-01-19 개시 Goldman Sell
2021-04-20 개시 Goldman Neutral
2021-04-20 개시 Piper Sandler Overweight
2021-04-20 개시 SVB Leerink Outperform
모두보기

디자인 테라 주식(DSGN)의 최신 뉴스

pulisher
Jun 12, 2025

Design Therapeutics Confirms Directors at Annual Meeting - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Design Therapeutics reports voting results from annual meeting - Investing.com

Jun 12, 2025
pulisher
Jun 07, 2025

Squarepoint Ops LLC Has $297,000 Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Friedreich's Ataxia Market Poised for Rapid Expansion During the Forecast Period (2025-2034) as Drug Pipeline Gains Momentum | DelveInsight - The Malaysian Reserve

Jun 05, 2025
pulisher
Jun 05, 2025

BNP Paribas Financial Markets Makes New Investment in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Nuveen Asset Management LLC Sells 54,550 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Two Sigma Investments LP Trims Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Millennium Management LLC Acquires New Shares in OnKure Therapeutics (NASDAQ:OKUR) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Design Therapeutics starts Friedreich ataxia patient trial By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Transcript : Design Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 02 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

RBC Capital maintains Design Therapeutics stock rating with $5 target - Investing.com Australia

Jun 04, 2025
pulisher
Jun 04, 2025

RBC Capital maintains Design Therapeutics stock rating with $5 target By Investing.com - Investing.com South Africa

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics (DSGN) Advances Friedreich Ataxia Clinical T - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics starts Friedreich ataxia patient trial - Investing.com

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Announces Start Of Friedreich Ataxia Patient Dosing Ex-U.S. In Its Restore-Fa Phase 1/2 Multiple-Ascending Dose Trial Of Dt-216P2 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2 - The Manila Times

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics, Inc. Reports Initial Safety Data for DT-216P2 in Friedreich Ataxia Trial Amid FDA Clinical Hold on U.S. IND Application - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Makes New $71,000 Investment in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Bank of America Corp DE Sells 556,157 Shares of Aegon Ltd. (NYSE:AEG) - Defense World

Jun 04, 2025
pulisher
May 29, 2025

40,289 Shares in Design Therapeutics, Inc. (NASDAQ:DSGN) Acquired by BNP Paribas Financial Markets - Defense World

May 29, 2025
pulisher
May 28, 2025

Design Therapeutics to Participate in 2025 Jefferies Global Healthcare Conference - TradingView

May 28, 2025
pulisher
May 28, 2025

Clinical-Stage Biotech Design Therapeutics Set for Major Jefferies Healthcare Conference Presentation - Stock Titan

May 28, 2025
pulisher
May 28, 2025

Autodesk (NASDAQ:ADSK) Price Target Raised to $376.00 at Citigroup - Defense World

May 28, 2025
pulisher
May 27, 2025

Myotonic Dystrophy Market to Expand Significantly by 2034, - openPR.com

May 27, 2025
pulisher
May 27, 2025

As Gold Pushes Higher, Junior Miners Begin to Show Signs of Life - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Palantir vs. IBM: The Breakthrough Wall Street Is Missing - The Globe and Mail

May 27, 2025
pulisher
May 27, 2025

Is Pfizer Stock a Buy After This $1.25 Billion Investment? - The Globe and Mail

May 27, 2025
pulisher
May 25, 2025

Northern Trust Corp Purchases 51,351 Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 25, 2025
pulisher
May 22, 2025

3 Penny Stocks With Market Caps As Low As $70M To Watch - Yahoo Finance

May 22, 2025
pulisher
May 20, 2025

Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox - Genetic Engineering and Biotechnology News

May 20, 2025
pulisher
May 20, 2025

Promontory Therapeutics Announces Successful End of Phase 2 Meeting with US FDA on Phase 3 Registrational Study Design for PT-112 in Patients with Metastatic Castration-Resistant Prostate Cancer - PR Newswire

May 20, 2025
pulisher
May 19, 2025

Price T Rowe Associates Inc. MD Decreases Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN) - Defense World

May 19, 2025
pulisher
May 16, 2025

Design Therapeutics, Inc. (NASDAQ:DSGN) Stock Holdings Increased by Dimensional Fund Advisors LP - Defense World

May 16, 2025
pulisher
May 14, 2025

Leerink Partnrs Analysts Lower Earnings Estimates for DSGN - The AM Reporter

May 14, 2025
pulisher
May 13, 2025

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Quantum Sandbox Act: Why These 3 Quantum Stocks Could Be Ready to Explode - The Globe and Mail

May 13, 2025
pulisher
May 12, 2025

Q2 EPS Forecast for Design Therapeutics Reduced by Analyst - Defense World

May 12, 2025
pulisher
May 12, 2025

Chardan Capital Issues Optimistic Forecast for CRSP Earnings - Defense World

May 12, 2025
pulisher
May 12, 2025

FY2025 EPS Estimates for EYPT Decreased by Cantor Fitzgerald - Defense World

May 12, 2025
pulisher
May 12, 2025

Wells Fargo & Company MN Boosts Stock Holdings in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 12, 2025
pulisher
May 12, 2025

FY2025 Earnings Forecast for GPCR Issued By Leerink Partnrs - Defense World

May 12, 2025
pulisher
May 09, 2025

Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer - The Globe and Mail

May 09, 2025
pulisher
May 08, 2025

Ataxia Pipeline: Advancing Therapeutics and 32+ Leading - openPR.com

May 08, 2025
pulisher
May 08, 2025

Barclays PLC Has $639,000 Stock Position in Design Therapeutics, Inc. (NASDAQ:DSGN) - Defense World

May 08, 2025
pulisher
May 08, 2025

Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale - Morningstar

May 08, 2025
pulisher
May 07, 2025

Design Therapeutics Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - marketscreener.com

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results - The Manila Times

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics, Inc. SEC 10-Q Report - TradingView

May 07, 2025
pulisher
May 07, 2025

Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter ... - Bluefield Daily Telegraph

May 07, 2025

디자인 테라 (DSGN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

디자인 테라 주식 (DSGN) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
William Arsani
Director
Aug 09 '24
Sale
4.25
814,874
3,463,214
0
$20.42
price down icon 1.37%
$35.45
price up icon 0.65%
$21.06
price down icon 1.92%
$101.83
price down icon 0.41%
$105.86
price down icon 0.39%
biotechnology ONC
$244.00
price down icon 3.69%
자본화:     |  볼륨(24시간):